Associated Banc Corp acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 99,391 shares of the healthcare product maker’s stock, valued at approximately $9,823,000.
Other institutional investors have also bought and sold shares of the company. BlackRock Inc. grew its holdings in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after buying an additional 6,769,518 shares in the last quarter. State Street Corp raised its holdings in shares of Abbott Laboratories by 1.7% during the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock worth $7,343,246,000 after acquiring an additional 1,350,766 shares during the period. Bank of America Corp DE purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth $1,603,607,000. Deutsche Bank AG boosted its position in shares of Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Abbott Laboratories during the 2nd quarter valued at about $1,082,524,000. 75.18% of the stock is owned by hedge funds and other institutional investors.
Abbott Laboratories Stock Performance
NYSE ABT opened at $109.43 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market cap of $189.35 billion, a P/E ratio of 40.83, a P/E/G ratio of 1.93 and a beta of 0.54. The business’s 50-day moving average price is $104.09 and its 200 day moving average price is $101.91. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02.
Abbott Laboratories Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is 94.03%.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on ABT shares. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Wall Street Zen raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Argus downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. UBS Group decreased their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.32.
Check Out Our Latest Research Report on ABT
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.
Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.
The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.
Read More
- Five stocks we like better than Abbott Laboratories
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
